buy

Alnylam Pharmace. buy JPMorgan Chase & Co.

Alnylam Pharmace.

Start price

€264.00

/ 50%

Target price

12.06.26

Performance (%)

Price

Summary

This prediction is currently active. The prediction currently has a performance of . This prediction currently runs until 12.06.26. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

Feedback

Performance without dividends (%)

Name	1w	1m
Alnylam Pharmace.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by JPMorgan_Chase___Co_ for this prediction

In the thread Alnylam Pharmace. diskutieren

Prediction Buy

Perf. (%)

Target price 296.257

Change

Ends at

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at JPMorgan Chase & Co. from $330.00 to $338.00. They now have an "overweight" rating on the stock.

Ratings data for ALNY provided by MarketBeat

JPMorgan Chase & Co.